StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$920.69−2.65 (-0.29%)

Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –

Regeneron Pharmaceuticals Direct Research and Development Expenses — Total by Quarter

Direct Research and Development Expenses — Total ($M) ($M)

Regeneron Pharmaceuticals Direct Research and Development Expenses — Total: $590M in Q3 2026, up 29.8% from a year earlier.

Latest, Q3 2026
590
Period ended Sep 30, 2026
Change on a year earlier
+29.8%
454 in Q3 2025
History
39 quarters
Since Q1 2017
Sources
36
Documents cited below

Where the Q3 2026 figure comes from

“R&D Expenses Table (FY2026Q3): Total direct research and development expenses | 589.6 | 454.3 | 135.3 | 1,627.5 | 1,296.7 | 330.8”

Source: Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗

Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses Summary Table.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDirect Research and Development Expenses — Total ($M) ($M)Year on yearSource
Q3 2026Sep 30, 2026590+29.8%Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Q2 2026Jun 30, 2026539+18.7%Form 10-Q (regn-20260630.htm, filed 2026-07-30) ↗
Q1 2026Mar 31, 2026499+28.4%Form 10-Q (regn-20260331.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 2025461+7.2%Form 10-K (regn-20251231.htm; 0000872589-26-000034|regn-20260930.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 2025454+17.6%Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Q2 2025Jun 30, 2025454+24.8%Form 10-Q (regn-20260630.htm, filed 2026-07-30) ↗
Q1 2025Mar 31, 2025388-4.9%Form 10-Q (regn-20260331.htm, filed 2026-04-29) ↗
Q4 2024Dec 31, 2024430+29.3%Form 10-K (regn-20251231.htm; 0000872589-25-000028|regn-20250930.htm, filed 2026-02-04) ↗
Q3 2024Sep 30, 2024386+21.0%Form 10-Q (regn-20250930.htm, filed 2025-10-28) ↗
Q2 2024Jun 30, 2024364+13.3%Form 10-Q (regn-20250630.htm, filed 2025-08-01) ↗
Q1 2024Mar 31, 2024408+26.6%Form 10-Q (regn-20250331.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 2023333-1.4%Form 10-K (regn-20251231.htm; 0001804220-24-000040|regn-20240930.htm, filed 2026-02-04) ↗
Q3 2023Sep 30, 2023319+12.5%Form 10-Q (regn-20240930.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 2023321+42.1%Form 10-Q (regn-20240630.htm, filed 2024-08-01) ↗
Q1 2023Mar 31, 2023322+64.7%Form 10-Q (regn-20240331.htm, filed 2024-05-02) ↗
Q4 2022Dec 31, 2022337+48.1%Form 10-K (regn-20241231.htm; 0001804220-23-000031|regn-20230930.htm, filed 2025-02-05) ↗

Breakdown

What makes up direct Research and Development Expenses — Total

Cite this data

StockData. (2026). Regeneron Pharmaceuticals Direct Research and Development Expenses — Total ($M), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-direct-tot

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?